CA3246379A1 - METHOD AND MOLECULES FOR REDUCING AXONAL TAU PROTEIN ACCUMULATION BY BLOCKING HNRNP R-MEDICATED MRNA TRANSPORT FOR THE TREATMENT OF ALZHEIMER'S DISEASE - Google Patents

METHOD AND MOLECULES FOR REDUCING AXONAL TAU PROTEIN ACCUMULATION BY BLOCKING HNRNP R-MEDICATED MRNA TRANSPORT FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Info

Publication number
CA3246379A1
CA3246379A1 CA3246379A CA3246379A CA3246379A1 CA 3246379 A1 CA3246379 A1 CA 3246379A1 CA 3246379 A CA3246379 A CA 3246379A CA 3246379 A CA3246379 A CA 3246379A CA 3246379 A1 CA3246379 A1 CA 3246379A1
Authority
CA
Canada
Prior art keywords
mapt
hnrnp
tau
mrna
motoneurons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3246379A
Other languages
English (en)
French (fr)
Inventor
Michael Anton SENDTNER
Michael BRIESE
Abdolhossein ZARE
Saeede SALEHI
Original Assignee
Julius Maximilians Universitaet Wuerzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Julius Maximilians Universitaet Wuerzburg filed Critical Julius Maximilians Universitaet Wuerzburg
Publication of CA3246379A1 publication Critical patent/CA3246379A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3246379A 2022-05-13 2023-03-13 METHOD AND MOLECULES FOR REDUCING AXONAL TAU PROTEIN ACCUMULATION BY BLOCKING HNRNP R-MEDICATED MRNA TRANSPORT FOR THE TREATMENT OF ALZHEIMER'S DISEASE Pending CA3246379A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263364629P 2022-05-13 2022-05-13
US63/364,629 2022-05-13
US202263382536P 2022-11-07 2022-11-07
US63/382,536 2022-11-07
PCT/EP2023/056392 WO2023217437A1 (en) 2022-05-13 2023-03-13 Method and molecules for reducing axonal tau protein accumulation through blocking of hnrnp r-mediated mapt mrna transport for treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
CA3246379A1 true CA3246379A1 (en) 2023-11-16

Family

ID=85685250

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3246379A Pending CA3246379A1 (en) 2022-05-13 2023-03-13 METHOD AND MOLECULES FOR REDUCING AXONAL TAU PROTEIN ACCUMULATION BY BLOCKING HNRNP R-MEDICATED MRNA TRANSPORT FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Country Status (6)

Country Link
US (1) US20250304958A1 (https=)
EP (1) EP4522217A1 (https=)
JP (1) JP2025517123A (https=)
AU (1) AU2023267136A1 (https=)
CA (1) CA3246379A1 (https=)
WO (1) WO2023217437A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI772856B (zh) * 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
AU2016215155A1 (en) * 2015-02-04 2017-08-17 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
AU2021238319A1 (en) * 2020-03-18 2022-10-06 University Of Massachusetts Oligonucleotides for MAPT modulation

Also Published As

Publication number Publication date
JP2025517123A (ja) 2025-06-03
WO2023217437A1 (en) 2023-11-16
EP4522217A1 (en) 2025-03-19
AU2023267136A1 (en) 2024-10-10
US20250304958A1 (en) 2025-10-02

Similar Documents

Publication Publication Date Title
Litvinchuk et al. Apolipoprotein E4 reduction with antisense oligonucleotides decreases neurodegeneration in a tauopathy model
Long et al. Novel upregulation of amyloid-β precursor protein (APP) by microRNA-346 via targeting of APP mRNA 5′-untranslated region: Implications in Alzheimer’s disease
US20230257743A1 (en) Use of p38 inhibitors to reduce expression of dux4
Zhang et al. MiR-214-3p attenuates cognition defects via the inhibition of autophagy in SAMP8 mouse model of sporadic Alzheimer's disease
Perez et al. Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia
JP2024513237A (ja) Ｔｄｐ－４３プロテイノパチーを処置するための組成物及び方法
EP3362564B1 (en) Nucleic acid based tia-1 inhibitors
US20210123051A1 (en) Uses for prevention or treatment of brain diseases using microrna
Roux et al. Modification of Mecp2 dosage alters axonal transport through the Huntingtin/Hap1 pathway
JP2018531046A6 (ja) 核酸ベースのｔｉａ−１阻害剤
Iqbal et al. Opportunities and challenges in developing Alzheimer disease therapeutics
WO2019229133A1 (en) Methods of treating or preventing an aging-related disease
US20170246200A1 (en) Microrna-132/212 for the treatment of neurodegenerative disorders
Gao et al. The mechanisms underlying TDP-43-associated neurodegeneration in Alzheimer’s disease and related dementias
US20250304958A1 (en) Method and molecules for reducing axonal tau protein accumulation through blocking of hnrnp r-mediated mapt mrna transport for treatment of alzheimer's disease
US12584133B2 (en) Antisense nucleic acid and use thereof
US12565650B2 (en) STAUFEN1 regulating agents and associated methods
Ahammad et al. Anti-Sense Oligonucleotide as a Therapeutic for Synucleinopathies: Pharmacokinetic, Safety and Efficacy Evaluation
KR20190051510A (ko) miR-485-3p를 이용한 알츠하이머병 진단 방법
Sun et al. Significant downregulation of Alzheimer's amyloid-β levels enabled by engineered DNA nanomaterials
US20220401428A1 (en) Method for Treatment of Alzheimer's Disease
Carlini et al. Identification of p38 MAPK inhibition as a neuroprotective strategy for combinatorial SMA therapy
US20260083766A1 (en) Methods to treat neurodegenerative disorders by reducing nuclear aggregates and modulating adenosine-to-inosine rna editing
US20250090568A1 (en) Method of treating long-covid induced neurologic diseases
Ahammad et al. Peptide-Mediated Delivery of α-Synuclein Targeting ASO: Pharmacokinetics, Safety, and CNS Efficacy in a Synucleinopathy Model

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240920

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240926

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240926

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240926

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20241123

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250213

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250220

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250220

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250220